Empowering Myeloid Cells to Better Address Unmet Clinical Needs

To maximize the drugability potential, we target approaches to improve clinical benefits based on reverse translational science and emerging biology of the tumor microenvironment.

  • (Reverse)Translational Science

    Clinical Experience   Basic Research

    Identification of patients' unmet needs, novel targets, pathways, and mechanisms.

  • Drug Discovery & Development

    Myeloid Engager

    Validation of target, mechanism of action, and proof of concept, and development of novel engager with high potency and good safety profile.

  • Immunotherapy

    Clinical Benefit

    Boosting of anti-tumor immunity to fight against cancer.

Our Myeloid Engager Platform

Novel Mechanism of Action

Direct engagement of myeloid cells with target cells.

Activation of killing mechanism (such as phagocytosis) by myeloid cells directed towards target cells.

Stimulation of myeloid cells to release minimal cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment and enhance cytotoxic T cell function.

Cross presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.

We have a global character of innateness
in our science & culture.

Latest News

LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline

REDWOOD CITY, Calif. and SHENZHEN, China July 30, 2024

REDWOOD CITY, Calif. & SHENZHEN, China – July 30, 2024 – LTZ Therapeutics, an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases. This round was led by new investor Lapam Capital and includes new investment participation from GL Ventures. In addition, the company has received continued investment from K2 Venture Partners and Shunwei Capital. The closing of this round brings LTZ’s total funding to approximately $50 million since the company was founded in 2022.

Follow Us
  • Stay ln Touch

    General Inquiries

    info@ltztherapeutics.com

    Business Development

    vivian.tian@ltztherapeutics.com
  • Locations

    Redwood City, USA

    1100 Island Dr., Suite 103, Redwood City, CA, 94065

    Shenzhen, China

    Room 209, Scientific Research Building, Tsinghua Hi-Tech Park, Nanshan District, Shenzhen, 518057

@ 2024 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us

为了更好的呈现效果,移动端请竖屏浏览